- Home
- ARGX
ARGX
argenx SE
as 02-21-2025 4:00pm EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Upcoming Earnings Alert:
Get ready for potential market movements as argenx SE ARGX prepares to release earnings report on 27 Feb 2025.
| Founded: | 2008 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 40.4B | IPO Year: | 2017 |
| Target Price: | $653.11 | AVG Volume (30 days): | 225.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $349.86 - $678.21 | Next Earning Date: | 02-27-2025 |
| Revenue: | $1,908,659,000 | Revenue Growth: | 85.56% |
| Revenue Growth (this year): | 73.18% | Revenue Growth (next year): | 55.26% |
Latest argenx SE News
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
Insider Monkey
3 days ago
Here’s Why argenx SE (ARGX) Rose in Q4
Thomson Reuters StreetEvents
3 days ago
Q4 2024 Halozyme Therapeutics Inc Earnings Call
Zacks
23 days ago
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Simply Wall St.
23 days ago
Exploring High Growth Tech Stocks With Promising Potential
Insider Monkey
a month ago
Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?
Insider Monkey
a month ago
Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?
Zacks
a month ago
Earnings Estimates Rising for Argenx (ARGX): Will It Gain?
Compare ARGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.